Enovis Corporation | Small-cap | Healthcare
$33.02
-1.87%
| Enovis Stock Comparison:
Enovis vs Abbott LaboratoriesEnovis vs Boston ScientificEnovis vs UFP TechnologiesEnovis vs Alphatec HoldingsEnovis vs NovocureEnovis vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 2.1B
Gross Profit 1.2B 56.02%
Operating Income -103.4M -4.91%
Net Income -824.8M -39.13%
EPS (Diluted) -$14.93

Balance Sheet Metrics

Total Assets 4.7B
Total Liabilities 2.2B
Shareholders Equity 2.6B
Debt to Equity 0.84

Cash Flow Metrics

Operating Cash Flow -529.0M
Free Cash Flow -67.2M

Revenue & Profitability Trend

Enovis Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue2.1B1.7B1.6B1.4B1.1B
Cost of Goods Sold926.9M716.4M693.7M648.5M517.1M
Gross Profit1.2B990.8M869.4M777.7M603.6M
Operating Expenses1.1B905.6M833.7M714.9M549.7M
Operating Income-103.4M-48.4M-90.7M-54.1M-49.4M
Pre-tax Income-822.9M-67.1M-2.1M-121.8M-119.0M
Income Tax4.5M-13.3M36.1M-19.5M-44.6M
Net Income-824.8M-32.7M-11.8M76.3M45.8M
EPS (Diluted)-$14.93-$0.61-$0.25$1.38$0.93

Income Statement Trend

Enovis Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets1.1B896.5M795.0M2.3B1.4B
Non-Current Assets3.6B3.6B3.5B6.2B6.0B
Total Assets4.7B4.5B4.3B8.5B7.4B
Liabilities
Current Liabilities529.0M369.6M565.2M1.0B811.7M
Non-Current Liabilities1.6B719.0M258.2M2.8B3.0B
Total Liabilities2.2B1.1B823.4M3.9B3.8B
Equity
Total Shareholders Equity2.6B3.4B3.4B4.7B3.6B

Balance Sheet Composition

Enovis Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income-824.8M-32.7M-11.8M76.3M45.8M
Operating Cash Flow-529.0M166.5M34.9M340.0M302.4M
Investing Activities
Capital Expenditures-180.7M-89.7M-102.7M-97.2M-105.2M
Investing Cash Flow-955.5M-242.5M-176.4M-320.5M-175.1M
Financing Activities
Dividends Paid-----
Financing Cash Flow846.8M-115.0M-1.4B1.2B-250.0M
Free Cash Flow-67.2M12.8M-161.3M251.9M187.2M

Cash Flow Trend

Enovis Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -2.01
Forward P/E 9.53
Price to Book 0.66
Price to Sales 0.80
PEG Ratio 9.53

Profitability Ratios

Profit Margin -37.65%
Operating Margin 0.90%
Return on Equity -27.35%
Return on Assets 0.92%

Financial Health

Current Ratio 2.55
Debt to Equity 55.68
Beta 1.83

Per Share Data

EPS (TTM) -$14.64
Book Value per Share $45.83
Revenue per Share $38.53

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
enov1.7B-2.010.66-27.35%-37.65%55.68
Abbott Laboratories 231.9B17.314.7530.65%31.89%27.09
Boston Scientific 149.9B73.946.759.50%11.58%52.16
UFP Technologies 1.9B29.895.2019.36%11.59%55.05
Alphatec Holdings 1.6B-9.63-18.581,144.21%-25.77%-6.76
Novocure 1.9B-10.905.12-45.52%-26.41%192.49

Financial data is updated regularly. All figures are in the company's reporting currency.